CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partnership with Imaging Specialists IAG Gives Tech Boost to Upcoming Brain Cancer Drug Trials
Oct 5, 2020
- Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”)
- CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials
- One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin
- CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to prepare, through its sub-licensee partner WPD Pharmaceuticals, for a first-ever Phase I pediatric trial of Berubicin in Poland as well as continuing the development of the company’s second drug candidate, WP1244, which has shown tremendous promise in stopping cancer proliferation in preclinical studies comparing it to chemotherapy drug daunorubicin
CNS Pharmaceuticals (NASDAQ: CNSP) is building its technologically advanced strategy for demonstrating the potential brain tumor-fighting capabilities of its novel drug Berubicin, announcing recently an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate upcoming clinical phase II patient trial scansin real time.
IAG’s proprietary platform DYNAMIKA is an AI-driven technology developed to aid in the analysis of patient responses during pharmaceutical trial’s, and IAG has extensive experience in partnering with the biotech industry — oncology companies in particular — to provide a centralized reading of…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
Oil Prices Climb on Continued Impasse in U.S.-Iran Talks
President Trump rejected Iran’s proposal over the weekend, calling it “unacceptable,” but Iran said it was still waiting for “definitive news” from Washington.
The Cure for Loneliness May Lie in a Suburban Duplex
Fresh pies. Book groups. Puzzle challenges. Developers of master-planned communities see fear of social isolation and desire for friends as a business opportunity. Welcome to Amity Lane.
What a US diesel export ban could mean for you
The threatened proposal aims to protect US consumers from rising costs, but it could trigger major economic waves if it were to happen.
Best thing we can offer young people is a job, not benefits, says chancellor
John Healey's speech comes ahead of next month's Budget, as he faces pressure to bring down government borrowing costs.
China and the U.S. Pledge to Cut Tariffs on $60 Billion in Goods
The two countries unveiled separate lists covering thousands of products as they sought to ease trade tensions and stabilize relations before further negotiations.
Aldi boss says some of rivals' loyalty discounts 'dupe' customers
Aldi is the only major supermarket chain that doesn't operate a loyalty scheme, which are hugely popular and used by millions of shoppers.
What is the Budget and what could be in it?
Chancellor John Healey will set out his plans for UK taxes in October.
UK needs plan in case of 'unprecedented' AI job losses, says minister
Kanishka Narayan says one of his top priorities is to have a plan in place if job losses are as bad as some fear.
Two of China’s EV Makers Announce a Deal as Auto Industry Moves Toward Consolidation
Two of the country’s leading makers of electric vehicles announced they are merging their battery swapping and charging operations.
Here’s What Fans Paid for Harry Styles Tickets at M.S.G.
We talked to 34 concertgoers about the time, money and effort they spent getting tickets for the star’s New York City residency.
Could A.I. Safety Risks Derail the Sector’s I.P.O. Prospects?
Big liability questions lie ahead for the artificial intelligence labs Anthropic and OpenAI as they push ahead with plans to go public.
Could Homeownership Reverse the Decline in Birthrates?
Researchers looked back at the baby-boom era and found that federal mortgage programs played a part in the country’s population upswing after World War II.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.